Prospects for the use of inositols in perimenopause

Results. This literature review describes the authors' data related to the use of inositols in perimenopausal women. During this period of life, women experience hormonal fluctuations and menopausal symptoms, leading to changes in the cardiovascular system and the risk of cardiac and metabolic disorders (atherosclerosis, increased visceral fat formation, critical blood lipid levels, chronic arterial hypertension, and insulin resistance). The researchers demonstrated reliable results supporting the use of inositol for metabolic syndrome in perimenopausal women, suggesting the use of inositols for associated conditions. Secondary messengers of insulin signaling (myoinositol, D-chiroinositol) and α-lipoic acid moderate the various effects of insulin, which is important during perimenopause. Studies have shown reductions in the HOMA index, glucose, insulin, triglycerides, low-density lipoprotein, and body mass index when taking dietary supplements containing the above-mentioned components, which restores ovulation and menstrual rhythm in women of reproductive age. The positive effects of myoinositol and D-chiroinositol, which help reduce the risk of cardiovascular disease, diabetes, and non-alcoholic fatty liver disease, have also been demonstrated in the perimenopausal period. The ratio of myoinositol to D-chiroinositol, 40:1, is physiological, as demonstrated by pharmacokinetic studies. Diferton is recommended as a dietary supplement and an additional source of inositol (B₈), alpha-lipoic acid, folic acid, vitamin D₃, and manganese for women not only with polycystic ovary syndrome in their reproductive years but also with impaired insulin sensitivity (primarily metabolic syndrome) in the perimenopausal period.

Conclusion. Future research and a fundamental understanding of the mechanism of action of myoinositol and D-chiro-inositol, particularly in combination with alpha-lipoic acid, manganese, folic acid, and vitamin D, will encourage their use as nutraceutical supplements to support optimal metabolism in the perimenopausal period.

1. Clinical guidelines. Menopause and climacteric state in women. Russian Society of Obstetricians and Gynecologists. 2025. 93 p. (In Russ.)

2. El Khoudary S. R., Greendale G., Crawford S. L., et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019; 26 (10): 1213-1227. DOI: 10.1097/GME.0000000000001424.

3. Zhang C., Zhao M., Li Z., Song Y. Follicle-Stimulating Hormone Positively Associates with Metabolic Factors in Perimenopausal Women. Int J Endocrinol. 2020; 2020: 7024321. DOI: 10.1155/2020/7024321.

4. Greendale G. A., Sternfeld B., Huang M., et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019; 4 (5): e124865. DOI: 10.1172/jci.insight.124865.

5. Yureneva S. V., Komedina V. I., Kuznetsov S. Yu. Diagnostic capabilities of anthropometric indicators for assessing obesity in women during the menopausal transition. Akusherstvo i ginekologiya. 2022; 2: 72-79. DOI: 10.18565/aig.2022.2.72-79. (In Russ.)

6. Fahed G., Aoun L., Bou Zerdan M., et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022; 23 (2): 786. DOI: 10.3390/ijms23020786.

7. Giordano D., Corrado F., Santamaria A., et al. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebocontrolled study. Menopause. 2011; 18 (1): 102-104. DOI: 10.1097/gme.0b013e3181e8e1b1.

8. Santamaria A., Giordano D., Corrado F., et al. One-year effects of myo inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric. 2012; 15 (5): 490-495. DOI: 10.3109/13697137.2011.631063.

9. D’Anna R., Santamaria A., Cannata M. L., et al. Effects of a new flavonoid and Myo-inositol supplement on some biomarkers of cardiovascular risk in postmenopausal women: a randomized trial. Int J Endocrinol. 2014; 2014: 653561. DOI: 10.1155/2014/653561.

10. Croze M. L., Soulage C. O. Potential role and therapeutic interests of myoinositol in metabolic diseases. Biochimie. 2013; 95: 1811-1827.

11. Kalra S., Kalra B. Inositols in midlife. J Mid-life Health. 2018; 9: 36-38.

12. Dobrokhotova Yu. E., Gromova O. A., Dukhanin A. S., Kumykova Z. Kh., Sheremetyeva E. V., Tabeeva G. I. Inositols: pharmacology and clinical trial data. Current status and prospects. RMZh. Mother and Child. 2022; 5 (4): 309-319. DOI: 10.32364/2618-8430-2022-5-4-309-319. (In Russ.)

13. Kalacheva A. G., Torshin Yu. U., Stelmashuk E. V., et al. Neuroprotective effect of myoinositol on the cellular model of glutamate stress as a basis for the prevention of disorders of intrauterine development of the brain. Farmakokinetika i farmakodinamika. 2018; 3: 9-20. DOI: 10.24411/2588-0519-2018-10018. (In Russ.)

14. Gromova O. A., Torshin I. Yu., Tetruashvili N. K. Prospects for the use of exogenous inositols to maintain the condition of the skin, hair and nails. Gynekologiya. 2022; 24 (4): 261-270. DOI: 10.26442/20795696.2022.4.20182. (In Russ.)

15. Gromova O. A., Torshin I. Yu., Tetruashvili N. K. The role of myoinositol in maintaining women's reproductive health. Improving the efficiency of in vitro fertilization technologies. RMZh. Mother and Child. 2018; 1 (1): 88-95. DOI: 10.32364/2618-8430-2018-1-1-88-95. (In Russ.)

16. Gromova O. A., Torshin I. Yu., Uvarova E. V., et al. Systematic analysis of the biological roles and pharmacological properties of D-chiroinositol. Gynekologiya. 2020; 22 (3): 21-28. DOI: 10.26442/20795696.2020.3.200210. (In Russ.)

17. Inositol. (Electronic resource.) URL: https://go.drugbank.com/drugs/DB13178 (access date: 20.10.2022).

18. López-Gambero A. J., Sanjuan C., Serrano-Castro P. J., et al. The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases. Biomedicines. 2020; 8 (9): 295.DOI: 10.3390/biomedicines8090295.

19. Clements R. S. Jr., Darnell B. Myo-inositol content of common foods: Development of a high-myo-inositol diet. Am J Clin Nutr. 1980; 33: 1954-1967.

20. Kiani A. K., Paolacci S., Calogero A. E., et al. From Myo-inositol to D-chiro inositol molecular pathways. Eur Rev Med Pharmacol Sci. 2021; 25 (5): 2390- 2402. DOI: 10.26355/eurrev_202103_25279.

21. Bizzarri M., Fuso A., Dinicola S., Cucina A., Bevilacqua A. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol. 2016; 12: 1181-1196.

22. Parazzini F. Resveratrol, inositol, vitamin D and K in the prevention of cardiovascular and osteoporotic risk: A novel approach in peri-and postmenopause. Minerva Ginecol. 2014; 66: 513-518.

23. Goldfine I. D. Does insulin need a second messenger? Diabetes. 1977; 26: 148-155.

24. Saltiel A. R., Cuatrecasas P. In search of a second messenger for insulin. Am J Physiol. 1988; 255: C1-11.

25. Benvenga S., Antonelli A. Inositol(s) in thyroid function, growth and autoimmunity. Rev Endocr Metab Disord. 2016; 17: 471-484.

26. Gao Y. F., Zhang M. N., Wang T. X., Wu T. C., Ai R. D., Zhang Z. S., et al. Hypoglycemic effect of D-chiro-inositol in Type 2 diabetes mellitus rats through the PI3K/Akt signaling pathway. Mol Cell Endocrinol. 2016; 433: 26-34.

27. Sun L., Dutta R. K., Xie P., Kanwar Y. S. Myo-inositol oxygenase overexpression accentuates generation of reactive oxygen species and exacerbates cellular injury following high glucose ambience: A new mechanism relevant to the pathogenesis of diabetic nephropathy. J Biol Chem. 2016; 291: 5688-707.

28. Tominaga T., Dutta R. K., Joladarashi D.,Doi T., Reddy J. K., Kanwar Y. S., et al. Transcriptional and translational modulation of myo-inositol oxygenase (Miox) by fatty acids: Implications in renal tubular injury induced in obesity and diabetes. J Biol Chem. 2016; 291: 1348-1367.

29. Chang H. H., Chao H. N., Walker C. S., Choong S. Y., Phillips A., Loomes K. M., et al. Renal depletion of myo-inositol is associated with its increased degradation in animal models of metabolic disease. Am J Physiol Renal Physiol. 2015; 309: F755-763.

30. Facchinetti F., Dante G., Neri I. The Ratio of MI to DCI and Its Impact in the Treatment of Polycystic Ovary Syndrome: Experimental and Literature Evidences. In: Frontiers in Gynecological Endocrinology. Genazzani A., Tarlatzis B., eds. Springer; 2016: 103-109. DOI: 10.1007/978-3-319-23865-4_13.

31. Carlomagno G., De Grazia S., Unfer V., Manna F. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv. 2012; 9 (3): 267-271. DOI: 10.1517/17425247.2012.662953.

32. Pestrikova T. Yu., Yurasova E. A., Yurasov I. V. Micronutrient support as a component of pre-conception preparation in assisted reproductive technology programs (literature review). Klinicheskii razbor v akusherstve, ginekologii i reproduktologii. 2021; 3 (1): 36-42. DOI: 10.47407/kragr2021.1.3.000023.

33. Dub N. V., Kruchinina E. V. Masks of polycystic ovary syndrome: the role of inositols. RMZh. Mother and Child. 2024; 3 (7): 205-213. DOI: 10.32364/2618-8430-2024-7-3-8.

34. Kutlakhmetova L. M., Lazarev D. M. Packaging for the dietary supplement Diferton. Industrial design patent RU 125166, May 13, 2021. Application No. 2020504750 dated October 13, 2020. eLIBRARY ID: 45818432.

35. Khabarov S. V., Andreevskaya T. V. Inozitol: vliyanie na reproduktivnuyu sistemu (obzor literatury) [Inositol: effects on the reproductive system (literature review)]. Vestnik novykh meditsinskikh tekhnologii. 2024; 1: 44-49. DOI: 10.24412/1609-2163-2024-1-44-49. EDN JBBYTG. (In Russ.)

36. Pustotina O. A. Inositol and lipoic acid in the treatment of insulin resistance in women with polycystic ovary syndrome. Akusherstvo i Ginekologiya. Akusherstvo i ginekologiya. 2020; 12: 209-216. (In Russ.) https://dx.doi.org/10.18565/aig.2020.12.209-216.

37. Ilyina I. Yu. Treatment of patients with polycystic ovary syndrome and metabolic syndrome. RMZh. Mother and Child. 2020; 4 (3): 254-259. DOI: 10.32364/2618-8430-2020-3-4-254-259. (In Russ.)

38. Chernukha G. E., Pronina V. A. Correction of metabolic dysfunction as a method of restoring the function of the reproductive system in women. Meditsinskii sovet. 2023; 5 (17): 90-97. DOI: 10.21518/ms2023-087. (In Russ.)

39. Khadzhieva N. Kh., Voznesenskaya T. G., Burchakova M. N. Factors in the development and non-hormonal correction of stress-related menstrual cycle disorders. Zhenskaya klinika. 2022; 2: 24-32. eLIBRARY ID: 49329495. (In Russ.)

40. Dikke G. B., Gavrilova E. A. Micronutrient support of ovarian function in patients with polycystic ovary syndrome. Zhenskaya klinika. 2021; 1: 16-23. eLIBRARY ID: 48344421. (In Russ.)

41. Vedzizheva E. R., Kuznetsova I. V. Dietary correction of metabolism in patients with polycystic ovary syndrome. Zhenskaya klinika. 2023; 4: 75-86. eLIBRARY ID: 64367644. (In Russ.)

42. Ivanov I. A., Tabeeva G. I., Smetnik A. A. Secondary messengers of insulin in polycystic ovary syndrome and methods of its pathogenetic correction. RMZh. Mother and Child. 2024; 2 (7): 135-143. DOI: 10.32364/2618-8430-2024-7-2-8. (In Russ.)

43. SGR Diferton Capsules, AM.01.20.01.003. R. 005. https://nsi.eaeunion.org/portal/1995.